


Second Edition

# Pharmaceutical Biotechnology

A PROGRAMMED TEXT

*Edited by*

**S. William Zito**



Second Edition

# Pharmaceutical Biotechnology

A PROGRAMMED TEXT

*Edited by*

**S. William Zito, Ph.D.**

Professor and Chair  
Department of Pharmaceutical Sciences  
St. John's University  
College of Pharmacy and Allied Health Professions  
Jamaica, New York 11420



LANCASTER • BASEL

## **Pharmaceutical Biotechnology**

a **TECHNOMIC**® publication

*Published in the Western Hemisphere by*  
Technomic Publishing Company, Inc.  
851 New Holland Avenue, Box 3535  
Lancaster, Pennsylvania 17604 U.S.A.

*Distributed in the Rest of the World by*  
Technomic Publishing AG  
Missionsstrasse 44  
CH-4055 Basel, Switzerland

Copyright © 1997 by Technomic Publishing Company, Inc.  
All rights reserved

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher.

Printed in the United States of America

10 9 8 7 6 5 4 3 2

Main entry under title:

Pharmaceutical Biotechnology: A Programmed Text, Second Edition

A Technomic Publishing Company book

Bibliography: p.

Includes index p. 265

Library of Congress Catalog Card No. 97-60885  
ISBN No. 1-56676-519-6



#### **HOW TO ORDER THIS BOOK**

BY PHONE: 800-233-9936 or 717-291-5609, 8AM-5PM Eastern Time

BY FAX: 717-295-4538

BY MAIL: Order Department  
Technomic Publishing Company, Inc.  
851 New Holland Avenue, Box 3535  
Lancaster, PA 17604, U.S.A.

BY CREDIT CARD: American Express, VISA, MasterCard

BY WWW SITE: <http://www.techpub.com>

#### **PERMISSION TO PHOTOCOPY-POLICY STATEMENT**

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Technomic Publishing Co., Inc. provided that the base fee of US \$3.00 per copy, plus US \$ .25 per page is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 1-56676/97 \$5.00 + \$ .25.

---

## Preface

---

The need for a second edition of this text can certainly be justified by the explosion of knowledge in the area of pharmaceutical biotechnology since the first edition was released in 1992. While new techniques and topics have been introduced to ensure that content is current, the format of the text has remained essentially unchanged. The text is designed to compliment existing courses in the pharmacy curriculum that may not be including biotechnology concepts in the formalized course structure. Chapters are sequenced to follow the progression of required scientific and clinical coursework found in the curricula of most pharmacy programs. The text begins with an overview of biotechnology principles and techniques. The various sections on pharmacy encompass both the basic pharmaceutical and clinical sciences. Included are chapters with focused biotechnology discussions relevant to medicinal chemistry, pharmacology, pharmaceutics, and pharmacotherapeutics. Each chapter contains specific learning objectives, as well as a pretest and posttest to allow assessment of content mastery after study.

This second edition benefits from the comments of colleagues who have utilized the first edition. As a result of their input, new authors have been added, and the chapters on Introduction to Recombinant DNA Technology, Medicinal Chemistry, Pharmacology, and Pharmacotherapeutics have been expanded. In addition, two new chapters on Pharmacokinetics of Peptide and Proteins, and Gene Therapy have been included. To our faculty colleagues, I trust you will find this text an effective way to incorporate the essential topic of biotechnology into the pharmacy curriculum. To our student readers, I hope you will enjoy this programmed method of learning about biotechnology and its importance to the practice of pharmacy.

My contributing colleagues and I wish to thank the Grant Awards to Pharmacy Schools (GAPS) program of the SmithKline Beecham Foundation for their financial support of the first edition of this text.

S. WILLIAM ZITO, Ph.D.  
Professor and Chair  
Department of Pharmaceutical Sciences



---

## CONTRIBUTORS

---

Albert Belmonte, Ph.D.  
Dean and Acting President  
Massachusetts College of Pharmacy and Allied Health Sciences  
179 Longwood Avenue  
Boston, MA 02155

Joanne M. Carroll, Ph.D.  
Assistant Professor of Pharmaceutical Sciences  
St. John's University  
College of Pharmacy and Allied Health Professions  
8000 Utopia Parkway  
Jamaica, NY 11439

John-Emery Konecsni, Ph.D.  
Assistant Dean for Allied Health  
St. John's University  
College of Pharmacy and Allied Health Professions  
8000 Utopia Parkway  
Jamaica, NY 11439

Stan Louie, Pharm.D.  
Assistant Professor of Clinical Pharmacy  
University of Southern California  
School of Pharmacy  
1985 Zonal Avenue  
Los Angeles, CA 90033

Somnath Pal, Ph.D.  
Assistant Professor of Pharmacy Administration  
St. John's University  
College of Pharmacy and Allied Health Professions  
8000 Utopia Parkway  
Jamaica, NY 11439

Indra K. Reddy, Ph.D.  
Associate Professor of Pharmaceutics  
Northeast Louisiana University  
School of Pharmacy  
700 University Avenue  
Monroe, LA 71209

Jay Rho, Pharm.D.  
Associate Professor of Clinical Pharmacy  
University of Southern California  
School of Pharmacy  
1985 Zonal Avenue  
Los Angeles, CA 90033

Victoria F. Roche, Ph.D.  
Professor and Associate Dean  
Creighton University  
School of Pharmacy and Allied Health Professions  
2500 California Plaza  
Omaha, NE 68178

Louis D. Trombetta, Ph.D.  
Professor of Pharmaceutical Sciences  
St. John's University  
College of Pharmacy and Allied Health Professions  
8000 Utopia Parkway  
Jamaica, NY 11439

Harvey L. Wiener, Ph.D.  
Bristol-Myers Squibb Co.  
Pharmaceutical Research Institute  
Neurodegenerative Disorders  
5 Research Parkway  
Wallingford, CT 06492

S. William Zito, Ph.D.  
Professor of Pharmaceutical Sciences  
St. John's University  
College of Pharmacy and Allied Health Professions  
8000 Utopia Parkway  
Jamaica, NY 11439



---

## CONTENTS

---

<i>Preface</i>	ix
<i>Contributors</i>	xi

### **1. THE BASIC PRINCIPLES OF RECOMBINANT DNA TECHNOLOGY** **1**

JOANNE M. CARROLL, Ph.D. and LOUIS D. TROMBETTA, Ph.D.

Introduction . . . . .	1
Learning Objectives . . . . .	1
Pre-Test . . . . .	1
Nucleic Acid Structure and Function . . . . .	2
Recombinant DNA . . . . .	5
Cloning a Gene . . . . .	8
Characterization of a DNA Clone . . . . .	17
Large-Scale Production of Recombinant Proteins . . . . .	19
Selected Readings . . . . .	20
Post-Test . . . . .	21

### **2. MEDICINAL CHEMISTRY AND PHARMACEUTICAL BIOTECHNOLOGY** **23**

VICTORIA F. ROCHE, Ph.D. and S. WILLIAM ZITO, Ph.D.

Introduction . . . . .	23
Learning Objectives . . . . .	24
Pre-Test . . . . .	24
Nucleic Acid Structure and Chemistry . . . . .	26
Gene Regulation of Protein Synthesis . . . . .	29
In Vitro DNA Synthesis . . . . .	31
Antisense Oligonucleotides . . . . .	32
Physicochemical Properties of Proteins . . . . .	32
In Vitro Degradation of Proteins . . . . .	46
Protein Metabolism . . . . .	46

Expression Systems . . . . .	57
Monoclonal Antibodies . . . . .	58
Structure-Activity Studies with Biologically Relevant Proteins . . . . .	80
Gene Manipulation and Replacement . . . . .	90
Biotechnology in Drug Design . . . . .	90
Approved Pharmaceutical Biotechnology and Related Products . . . . .	92
Selected Readings . . . . .	100
Post-Test. . . . .	101
<b>3. NEUROTRANSMITTER RECEPTOR FUNCTION</b>	<b>103</b>
HARVEY L. WIENER, Ph.D.	
Introduction . . . . .	103
Learning Objectives . . . . .	103
Pre-Test . . . . .	104
Receptors and Second Messenger Systems . . . . .	106
Turning Off the Signal . . . . .	116
Receptors and Disease . . . . .	121
Receptor Study Techniques and New Drug Discovery . . . . .	125
Advances in Receptor Pharmacology . . . . .	133
Future Directions . . . . .	134
Reading List . . . . .	135
Post-Test. . . . .	135
<b>4. STABILITY OF PEPTIDE AND PROTEIN DRUGS</b>	<b>137</b>
INDRA K. REDDY, Ph.D.	
Introduction . . . . .	137
Learning Objectives . . . . .	138
Pre-Test . . . . .	138
Current Biotechnologic Drugs in Development . . . . .	143
Degradation Pathways for Peptides and Proteins . . . . .	143
Improving Protein Stability . . . . .	150
Stability of Small Molecules versus Macromolecules . . . . .	152
Stability of Dipeptides . . . . .	152
Conclusions . . . . .	156
Selected Readings . . . . .	156
Post-Test. . . . .	157
<b>5. PROTEIN AND PEPTIDE DRUG DELIVERY</b>	<b>159</b>
INDRA K. REDDY, Ph.D.	
Introduction . . . . .	159
Learning Objectives . . . . .	159
Pre-Test . . . . .	160
General Considerations in the Delivery of Proteins and Peptides . . . . .	165
Routes of Delivery . . . . .	167
Penetration Enhancers . . . . .	174

Delivery Systems . . . . .	176
Controlled/Sustained Release Systems . . . . .	178
Conclusions . . . . .	181
Acknowledgements . . . . .	181
Selected Readings . . . . .	181
Post-Test. . . . .	182
<b>6. PHARMACOKINETICS OF PROTEIN AND PEPTIDE DRUGS</b>	<b>183</b>
INDRA K. REDDY, Ph.D. and ALBERT A. BELMONTE, Ph.D.	
Introduction . . . . .	183
Learning Objectives . . . . .	184
Pre-Test . . . . .	184
Fundamental Pharmacokinetic Parameters . . . . .	185
Problems in Pharmacokinetic Studies with Protein and Peptide Drugs . . . . .	193
Pharmacokinetics of Selected Protein and Peptide Drugs . . . . .	198
Conclusion . . . . .	201
References and Suggested Reading . . . . .	202
Post-Test. . . . .	202
<b>7. PHARMACOTHERAPEUTICS OF BIOTECHNOLOGY-PRODUCED DRUGS</b>	<b>205</b>
STAN LOUIE, Pharm.D. and JAY RHO, Pharm.D.	
Introduction . . . . .	205
Learning Objectives . . . . .	205
Pre-Test . . . . .	205
Monoclonal Antibodies . . . . .	207
Enzymes and Regulators of Enzyme Activity . . . . .	210
Hormones . . . . .	213
Hematopoietic Growth Factors . . . . .	217
Colony-Stimulating Factors . . . . .	224
Post-Test Questions . . . . .	232
<b>8. RECOMBINANT DNA AS A DIAGNOSTIC AND THERAPEUTIC AGENT IN HUMAN DISEASE</b>	<b>235</b>
JOANNE M. CARROLL, Ph.D.	
Introduction . . . . .	235
Learning Objectives . . . . .	236
Pre-Test . . . . .	236
Restriction Fragment Length Polymorphisms (RFLPs) . . . . .	236
Positional Cloning of a Disease Locus . . . . .	240
Human Genome Project . . . . .	242
DNA (Gene) Therapy . . . . .	245
Antisense Therapy . . . . .	248
Summary . . . . .	249

---

Selected Bibliography . . . . .	249
Post-Test. . . . .	251
<b>9. BIOETHICS AND THE NEW BIOTECHNOLOGY</b>	<b>253</b>
JOHN-EMERY KONECSNI, Ph.D., SOMNATH PAL, Ph.D. and S. WILLIAM ZITO, Ph.D.	
Introduction . . . . .	253
Learning Objectives . . . . .	253
Pre-Test . . . . .	253
Background . . . . .	254
Modern Health Care Advances Bring New Ethical Questions . . . . .	257
Biotechnological Case Studies . . . . .	258
Conclusion . . . . .	262
Selected Readings . . . . .	263
Post-Test. . . . .	263
Index	265

# The Basic Principles of Recombinant DNA Technology

**JOANNE M. CARROLL, Ph.D., and LOUIS D. TROMBETTA, Ph.D.**

*St. John's University  
College of Pharmacy and Allied Health Professions  
Jamaica, New York 11439*

## INTRODUCTION

The discovery and confirmation of DNA as the genetic material launched an era over the last fifty years that has seen an explosive growth in the fundamental understanding of how genes work and in the development of new technologies based on the manipulation of genes. These technologies have been applied to animal and plant breeding, drug development, and diagnosis and treatment of disease. Genetic engineering provides a new means to produce biologically important materials in quantities greater than could be derived from the natural sources. The selection of improved plant strains and animal breeds can be accelerated by the judicious use of DNA technology. Further, diagnosis of many genetic and viral diseases is now possible through the use of DNA probes. Understanding the pathology of many diseases has advanced as a result of the ability to probe these processes at the genetic level. Finally, the correction of genetic defects by gene replacement therapy has been initiated and strategies to combat infectious diseases and cancer are under development. This extraordinary and rapid progress launches an era of hopeful expectation and excitement about the vast knowledge yet to be discovered and elucidated.

## LEARNING OBJECTIVES

- (1) To review the fundamental concepts and terminology associated with DNA structure and gene expression.
- (2) To describe the basic strategy for cloning a gene.
- (3) To discuss the use of cDNA and genomic clones in the study of gene expression.
- (4) To discuss production of pharmaceuticals using recombinant DNA.

## PRE-TEST

Answer True or False

1. The two strands of DNA helix are joined by covalent bonds between the nitrogenous bases.

2. A nucleotide consists of a sugar, phosphate, and nitrogenous base.
3. Restriction enzymes randomly cut DNA.
4. The enzyme that catalyzes transcription is DNA polymerase.
5. Transfer RNA contains a codon and an amino acid binding site.
6. The genetic code is stored in the ribosomal RNA sequence.
7. Eukaryotic genomes contain more sequences than appear in the mature mRNAs that are translated.
8. Each gene can encode only one polypeptide.
9. A DNA probe will hybridize to a complementary sequence through the formation of hydrogen bonds.
10. Bacteriophages are enzymes that degrade foreign DNA.

---

Answers:	1. F	3. F	5. F	7. T	9. T
	2. T	4. F	6. F	8. F	10. F


---

## NUCLEIC ACID STRUCTURE AND FUNCTION

Investigations of bacteria and later viruses, called bacteriophages, led to the fundamental discovery that DNA and not protein constituted the genetic material. DNA satisfies the two criteria for functioning as the genetic material. First, it is replicated, providing a mechanism for faithfully passing a copy of the genetic information from generation to generation. Second, it functions as an informational molecule, specifically; it directs the synthesis of cellular proteins.

DNA consists of two strands wound in a double helix. The nucleotides of each strand are linked by covalent bonds between the 3' hydroxyl of one nucleotide and the 5' phosphate of the next. Synthesis of DNA strands always occurs in the 5' to 3' direction, since the growing chain has the 3' hydroxyl available to form a phosphodiester bond with the 5' phosphate of the incoming nucleotide. (Figure 1-1). The nitrogenous bases, which in DNA are of four types, adenine (A), thymine (T), cytosine (C) and guanine (G), form hydrogen bonds with the bases on the opposite strand according to the complementary base pairing rule; i.e., A-T and G-C. The two strands are antiparallel in orientation; i.e., one is 5'-3' and the complementary strand is 3'-5'.






**Figure 1-1.** Phosphodiester linkage.

The information for protein synthesis lies in the DNA base sequence. In distinction to prokaryotes, the more complex eukaryotic genes contain coding and non-coding regions (Figure 1-2). Those regions that contain information for the *synthesis of cellular proteins* are called *exons*, while the intervening regions, called *introns*, contain important information for regulating transcription and processing of transcripts. In eukaryotes, the primary transcript, or heteronuclear RNA, contains both intronic and exonic sequences. Specific splicing enzymes present in the nucleus recognize sequences at the intron-exon junctions, splice out the intronic sequences, and join the exonic sequences. Interestingly, recent experiments have revealed enzymatic activity residing within some RNAs, suggesting that ribozymes may contribute to processing RNA. The mature mRNA, which is transported to the cytoplasm, acquires a polyadenylated tail. One advantage of the eukaryotic arrangement is that multiple transcripts can be derived from the same gene by alternative splicing of the primary transcript increasing the informational content. Alternately, spliced transcripts have been observed in the tissue-specific processing of proteins (Figure 1-2).

Ribonucleic acid, RNA, is involved in the reading of the genetic code in the DNA and its expression as protein molecules in a cell. RNA is a single stranded molecule containing a ribose sugar and having thymidine (T) replaced by uracil (U). The synthesis of RNA from the DNA template catalyzed by RNA polymerase is transcription (Figure 1-3). The code inscribed in the mRNA is translated into protein at the ribosome. The nucleotide sequence is read in triplets called *codons*, each codon designating a specific amino acid. Transfer RNA contains an anticodon that forms hydrogen bonds with the mRNA codon containing the complementary triplet of bases. The tRNA also contains an amino acid



**Figure 1-2.**

binding site and becomes charged with a specific amino acid in the cytoplasm. This amino acid is brought to the protein synthesis site at the ribosome and inserted into the growing polypeptide chain when the complementary codon of the mRNA sits in that site.

An understanding of these fundamental mechanisms is the basis for their application to practical problems exemplified by the emergence of genetic engineering and DNA biotechnology. Some goals of this research include correction of genetic defects by replacement of mutant genes with normal ones; accelerating selection of improved crops by introduction of useful genes into plants; improved diagnosis of viral, oncogenic, and genetic diseases; and better understanding of the pathological processes in disease and large-scale production of therapeutic proteins.

## RECOMBINANT DNA

Three key discoveries provided the basis for engineering recombinant DNA molecules, that is, molecules in which a piece of DNA is inserted into a particular site in another piece of DNA. The first was the discovery of restriction enzymes, which cut the DNA at sequence specific sites. These exist in bacteria along with modification enzymes, which together provide a restriction-modification system for degrading foreign DNA while protecting the bacteria's own DNA. The bacteria tag their own DNA with methylated groups via specific modification systems and protect it from degradation by restriction enzymes. To date, hundreds of restriction enzymes have been purified from various strains of bacteria and their sequence specificities determined. Each enzyme binds to the DNA at sequence-specific sites and cleaves the helix at specific nucleotide residues. This site is called the *recognition sequence*. Recognition sites consisting of four base pairs are relatively more frequent in the genome than those of six or eight base pairs. DNA incubated with restriction enzymes under appropriate incubation conditions will yield fragments of double stranded molecules of varying lengths depending upon the frequency of sites for that enzyme within the DNA. When DNA is cut by a restriction enzyme, the fragments may possess blunt ends or single stranded tails. Sticky, or cohesive ends, result if the two strands are not cut at the corresponding bases in both strands (Figure 1-4). The sticky ends may then be annealed to other DNA molecules that contain complementary sequence. The reannealed DNA fragments are joined together by DNA ligase, an enzyme that catalyzes the formation of phosphodiester bonds between adjacent nucleotides. These provide the basic tools with which to recombine DNA fragments from different sources, i.e., generate recombinant molecules.

The isolation of sufficient amounts of material to analyze gene structure and function requires synthesizing many copies of the DNA sequence. This relies on the introduction of the sequence into a vector, which can be amplified in bacterial hosts. An important step that facilitated gene cloning was the discovery of plasmids. A plasmid is an extrachromosomal piece of circular DNA that is replicated in bacteria. These genetic elements often carry genes for sex factors and antibiotic resistance and are found in multiple copies in bacterial cells. Plasmids are transferable from bacteria to bacteria. Bacterial cultures are treated so that the cells become competent to take up DNA from the media environment by the process of transformation. Once inside the bacterial cells, the plasmids replicate. Plasmids have been designed that replicate to high copy numbers in bacterial hosts, which dramatically increases the yield of recombinant DNA that can be prepared from a bacterial culture. Plasmids differ structurally from the large chromosomal DNA and are easily